Pasithea Therapeutics Acquires AlloMek Therapeutics

BioMarin Acquires Alesta Therapeutics

August 18, 2026

Biotechnology

BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, plus up to $215 million in development and regulatory milestone payments, to obtain its lead clinical-stage asset, ALE1. The acquisition closed on September 1, 2026; Alesta had spun out its non-ALE1 assets before closing, and became a wholly owned BioMarin subsidiary.

Tarsus Pharmaceuticals Acquires Alkeus Pharmaceuticals

August 6, 2026

Biotechnology

Tarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals for approximately $450 million upfront—$270 million in cash and $180 million in Tarsus stock—with up to $350 million in milestone payments and tiered royalties. Tarsus completed the acquisition on September 4, 2026, adding worldwide rights to Alkeus’s Phase 3 Stargardt disease therapy, gildeuretinol (ALK-001), to expand its retina pipeline and eye-care portfolio.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

June 22, 2022

Biotechnology

Pasithea Therapeutics Corp. acquired all outstanding equity interests in Alpha-5 Integrin, LLC, a preclinical biotechnology company developing a monoclonal antibody targeting α5 integrin for ALS and other neuroinflammatory disorders. The transaction was valued at $3.75 million and was paid primarily in Pasithea common stock (3,260,870 shares) plus warrants; an entity controlled by Paul B. Manning was Alpha-5's majority owner prior to the deal.

PureTech Acquires Remaining Interest in Alivio Therapeutics

June 16, 2021

Biotechnology

PureTech Health plc acquired the remaining 22% of shares in its Founded Entity, Alivio Therapeutics, integrating Alivio's anti-inflammatory therapeutic programs — including LYT-500 and LYT-503/IMB-150 — into PureTech's Wholly Owned Pipeline. The transaction consolidates PureTech's ownership of Alivio and is expected to fund and advance the programs through PureTech's immunology and related technology capabilities.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.